About Iambic Therapeutics
Iambic Therapeutics is a biotechnology company leveraging artificial intelligence and machine learning to revolutionize drug discovery and development. The company integrates advanced computational chemistry, AI-powered molecular design, and experimental validation to accelerate the creation of novel small molecule therapeutics. Iambic's platform combines predictive modeling, structure-based drug design, and high-throughput screening to identify and optimize drug candidates with improved efficacy and safety profiles. The company's approach enables rapid iteration through design-make-test cycles, significantly reducing the time and cost associated with traditional drug discovery. Iambic focuses on developing precision medicines for complex diseases where there are significant unmet medical needs. By bridging computational predictions with experimental biology, the company aims to bring transformative therapies to patients faster than conventional methods. Their integrated platform allows for the systematic exploration of chemical space and the rational design of molecules with desired pharmacological properties, positioning them at the forefront of AI-enabled pharmaceutical innovation.
Who It Serves
Social & Media
Follow on
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.